IRWD News and Press, Ironwood Pharmaceuticals Inc. From 11/27/23

2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible th...

2023-11-09 14:56:37 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Ironwood Pharmaceuticals: The Right Play Now Ironwood ...

2023-11-09 10:39:02 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Conference Call November 09, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Offi...

2023-11-09 07:03:18 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: The Right Play Now Ironwood: Pipeline Progresses As FDA Approves LINZESS Ironwood Pharmaceuticals Q3 2023 Earnings Preview JMP starts Ironwood at market outperform, cites potent...

– LINZESS ® (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million, an increase of 7% year-over-year – – Reported positive final data from STARS Nutrition, a Phase II study of apraglutide in shor...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $0.17 for Q3 2023

2023-11-08 13:37:25 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: The Right Play Now Ironwood: Pipeline Progresses As FDA Approves LINZESS JMP starts Ironwood at market outperform, cites potential of GLP-2 drug Seeking Alpha’s Quant Rat...

2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...